Upload
rosella-anstine
View
545
Download
1
Embed Size (px)
DESCRIPTION
Citation preview
PLANNING FOR ADULT VACCINATION WORKSHOP AERAS - SEPT 4, 5, 2013
Carla Botting
Director Product Development and Access
Malaria Vaccines Change from control to elimination/ eradication
2
Malaria epidemiology:
• Globally, 3.3 billion at risk of malaria*
• ~219 million (154M-289M) cases/year, 79% in sub-Saharan Africa
• 90% of these cases are caused by P. falciparum
• ~660,000 (490K-896K) deaths/year, 90% in sub-Saharan Africa
* WHO World Malaria Report 2012
Gething, P.W., et al., A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J, 2011. 10: p. 378.
Pf EIR
>100
10
1
0.1
Malaria Disease Burden
3
2006 Malaria vaccine community goal
Strategic Goal * : To develop an 80% efficacious malaria vaccine by 2025 that would provide protection for at least four years
– Landmark Goal: To develop and license
a first-generation malaria vaccine that has
protective efficacy of more than 50%
against severe disease and death and
lasts longer than one year
Malaria Vaccine Technology Roadmap http://www.malariavaccineroadmap.net/
*WHO is currently leading the process to revise to the Strategic Goal – the Landmark Goal will not change
4 4
Updated Strategic Goal & Outcomes
• A world free of malaria in part due to affordable access to
malaria vaccines that prevent disease and death caused by
and/or interrupt transmission of P. falciparum and P. vivax
in all ages and in all endemic settings.
Goal/Impact
Saving Lives
& Preventing
Disease
Control &
Elimination
Cases
Averted* Outcome Infections
Prevented
Transmission
Interrupted
*Impact on
asymptomatic
reservoir?
5 5
Updated Strategic Goal, Outcomes, & Targets
• A world free of malaria in part due to affordable access to
malaria vaccines that prevent disease and death caused by
and/or interrupt transmission of P. falciparum and P. vivax
in all ages and in all endemic settings.
Sexual/ Sporogonic/ Mosquito
(SSM)
Pre- erythrocytic
(PE)
Blood Stage (BS)
Goal/Impact Saving Lives
& Preventing
Disease
Control &
Elimination
Cases
Averted* Outcome Infections
Prevented
Transmission
Interrupted
Vaccine Target
6 6
Three priority program areas
• A world free of malaria in part due to affordable access to
malaria vaccines that prevent disease and death caused by
and/or interrupt transmission of P. falciparum and P. vivax
in all ages and in all endemic settings.
Goal/Impact
Saving Lives
& Preventing
Disease
Control &
Elimination
Cases
Averted* Outcome Infections
Prevented
Transmission
Interrupted
Vaccine Target
Next Gen TBVs ppRTS,S & eeRTS,S
4 priority program areas
7
RTS,S present and future
ppRTS,S Prevention of pediatric
malaria RTS,S
eeRTS,S Elimination / eradication
RTS,S
eeRTS,S+ Next generation elimination
/ eradication RTS,S
Current TPP for RTS,S, which focuses on prevention of pediatric malaria clinical and severe disease
Evaluation of current RTS,S construct to determine whether it could facilitate elimination in some settings Would require
deploying the current construct to the entire population at risk, not just infants / toddlers
Adding components to the current RTS,S construct to make a more highly efficacious malaria vaccine that could contribute to elimination in an entire at risk population
THANK YOU